Tag: Pharma
Astellas Pharma Acquires Iveric Bio For $5.9 Billion
Astellas Pharma Inc has reached an agreement to acquire Iveric Bio Inc for $5.9 billion in cash, valuing each share at $40.00.
Astellas has made...
Sun Pharma’s Antitrust Settlement Approved
Sun Pharmaceutical has settled its antitrust litigation with a settlement valued between $75 million to $95 million, having been accused of participating in an...
FTC OKs Hikma Pharma Acquisition With Conditions
Generic drug maker Hikma Pharmaceuticals has won US antitrust approval to buy Custopharm, Inc on condition that it divest an injectable steroid, the US...
UK Tribunal Upholds Fine For Pay For Delay Pharma Deals
The UK's Competition Appeal Tribunal has upheld the Competition and Markets Authority (CMA) decision that GlaxoSmithKline and some generic suppliers of the anti-depressant paroxetine...
UK Court Upholds CMA Decision On Pharma Collusion
The Competition Appeal Tribunal upheld the CMA’s finding on Thursday, February 25, that Lexon broke competition law and dismissed Lexon’s appeal.Last year, the...
Pharma Giant Charged With Price-Fixing In Generics Probe
The Justice Department (DOJ) on Tuesday, June 30, charged generic drug giant Glenmark Pharmaceuticals with manipulating the prices of drugs sold in the US,...
Novartis Scraps 1B Asset Sale, Including COVID-19 Treatment To Aurobindo Pharma
Novartis on Thursday, April 2, scrapped the US$1 billion sale of US generic pill and skin drug assets to India's Aurobindo Pharma as regulators...
Pharmacy Group Says There is No Antitrust Scheme in Curbing Drug...
A consortium of pharmacy trade groups fired back at claims they’re conspiring to “choke off” online information about affordable Canadian drugs, arguing in Manhattan...
Sandoz Agrees to Pay $195M Criminal Fine, Largest For A US...
Sandoz a generic pharmaceutical company headquartered in New Jersey, was charged for conspiring to allocate customers, rig bids, and fix prices for generic drugs,...
Gilead To Buy Forty Seven, Cancer Therapy Specialist For $4.9B
Gilead Sciences agreed to buy Forty Seven for about US$4.9 billion to advance into one of the hottest areas of pharmaceutical research, cancer treatments...
